New England Journal of Medicine
May 15, 2014 Vol. 370 No. 20
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Treating Hepatitis C in Lower-Income Countries
Channa R. Jayasekera, M.D., Michele Barry, M.D., Lewis R. Roberts, M.B., Ch.B., Ph.D., and Mindie H. Nguyen, M.D.
N Engl J Med 2014; 370:1869-1871May 15, 2014DOI: 10.1056/NEJMp1400160
Excerpt
With costs that may exceed $90,000 per course, effective new hepatitis C treatments seem beyond the reach of low- and middle-income countries. But the global rollout of HIV treatment teaches us that it’s possible to make these agents broadly available and affordable.

Editorial
Advancing the Treatment for Chagas’ Disease
Pedro Albajar-Viñas, M.D., Ph.D., and João Carlos P. Dias, M.D.
N Engl J Med 2014; 370:1942-1943May 15, 2014DOI: 10.1056/NEJMe1403689
Excerpt
It is estimated that 8 million people are infected with Trypanosoma cruzi worldwide, with the majority of cases occurring in the Latin American countries in which the parasite is endemic. However, cases of Chagas’ disease have been increasingly detected in the United States, Canada, many European countries, and some Western Pacific countries, owing primarily to an increase in population movements between Latin America and other continents. Moreover, some countries in which the parasite is not endemic have higher estimated numbers of cases than many endemic countries in Latin America (e.g., >300,000 cases in the United States and >50,000 in Spain). . . .